These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 15488203)

  • 1. Chlamydia, gonorrhoea, and injectable progesterone.
    Dayan L; Donovan B
    Lancet; 2004 Oct 16-22; 364(9443):1387-8. PubMed ID: 15488203
    [No Abstract]   [Full Text] [Related]  

  • 2. Sexually transmitted infections among women randomised to depot medroxyprogesterone acetate, a copper intrauterine device or a levonorgestrel implant.
    Deese J; Philip N; Lind M; Ahmed K; Batting J; Beksinska M; Edward VA; Louw CE; Onono M; Palanee-Phillips T; Smit JA; Baeten JM; Donnell D; Mastro TD; Mugo NR; Nanda K; Rees H; Morrison C
    Sex Transm Infect; 2021 Jun; 97(4):249-255. PubMed ID: 33208512
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Injectable use may increase women's odds of getting chlamydia or gonorrhea.
    MacLean R
    Int Fam Plan Perspect; 2005 Mar; 31(1):45-6. PubMed ID: 15997501
    [No Abstract]   [Full Text] [Related]  

  • 4. Is a lower-dose, subcutaneous contraceptive injectable containing depot medroxyprogesterone acetate likely to impact women's risk of HIV?
    Polis CB; Achilles SL; Hel Z; Hapgood JP
    Contraception; 2018 Mar; 97(3):191-197. PubMed ID: 29242082
    [No Abstract]   [Full Text] [Related]  

  • 5. Injectable contraception.
    Mishell DR
    J Reprod Med; 2002 Sep; 47(9 Suppl):777-9. PubMed ID: 12380405
    [No Abstract]   [Full Text] [Related]  

  • 6. New aspects of injectable contraception.
    Phillips OP
    Int J Fertil Womens Med; 2001; 46(1):31-6. PubMed ID: 11294618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized assignment to copper IUD or depot-medroxyprogesterone acetate: feasibility of enrollment, continuation and disease ascertainment.
    Feldblum PJ; Caraway J; Bahamondes L; El-Shafei M; Quan Ha D; Morales E; Wevill S; Condon S
    Contraception; 2005 Sep; 72(3):187-91. PubMed ID: 16102553
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppressive biological mechanisms support reassessment of use of the injectable contraceptive medroxyprogesterone acetate.
    Hapgood JP
    Endocrinology; 2013 Mar; 154(3):985-8. PubMed ID: 23429710
    [No Abstract]   [Full Text] [Related]  

  • 9. Depot medroxyprogesterone injectable contraception at the University of Uyo Teaching Hospital, Uyo.
    Abasiattai AM; Udoma EJ; Ukeme E
    Ann Afr Med; 2010; 9(2):81-5. PubMed ID: 20587929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin-only contraception: injectables and implants.
    Jacobstein R; Polis CB
    Best Pract Res Clin Obstet Gynaecol; 2014 Aug; 28(6):795-806. PubMed ID: 24996766
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Urinary tract infection in the users of depot-medroxyprogesterone acetate.
    Berger RE
    J Urol; 2005 Sep; 174(3):941. PubMed ID: 16093999
    [No Abstract]   [Full Text] [Related]  

  • 12. [Prevalence of Chlamydia trachomatis and Neisseria gonorrhoea infections in sexual actives young women at a southern Brazilian city].
    Piazzetta RC; de Carvalho NS; de Andrade RP; Piazzetta G; Piazzetta SR; Carneiro R
    Rev Bras Ginecol Obstet; 2011 Nov; 33(11):328-33. PubMed ID: 22267110
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-acting hormonal contraceptives--indispensable in preventing teen pregnancy.
    Kaunitz AM
    J Adolesc Health; 2007 Jan; 40(1):1-3. PubMed ID: 17185200
    [No Abstract]   [Full Text] [Related]  

  • 14. Current options for injectable contraception in the United States.
    Kaunitz AM
    Semin Reprod Med; 2001 Dec; 19(4):331-7. PubMed ID: 11727175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prevalence and predictors of chlamydia co-infection among patients infected with gonorrhoea at a sexual health clinic in Sydney.
    Templeton DJ; Manokaran N; O'Connor CC
    Sex Health; 2012 Sep; 9(4):392-4. PubMed ID: 22877601
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [An introductory clinical trial of three-monthly injectable contraceptive-depot medroxyprogesterone acetate].
    Shao Q; Jiang H; Fu W
    Zhonghua Fu Chan Ke Za Zhi; 1999 Jan; 34(1):36-9. PubMed ID: 11263172
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Injectable depot medroxyprogesterone acetate contraception: an update for U.S. clinicians.
    Kaunitz AM
    Int J Fertil Womens Med; 1998; 43(2):73-83. PubMed ID: 9609206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Injectable contraception.
    Roy G
    Semin Reprod Med; 2010 Mar; 28(2):126-32. PubMed ID: 20352562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effectiveness of injectable contraceptives in Mexican women].
    Garza-Flores J; Rodríguez V; Cravioto MC; del Real Mora O; Anderson J; Landeros J; Díaz Sánchez V; Lichtenberg R; Pérez-Palacios G
    Bol Oficina Sanit Panam; 1985 Feb; 98(2):181-6. PubMed ID: 3156612
    [No Abstract]   [Full Text] [Related]  

  • 20. Depo Provera increases risk for chlamydial, gonococcal infections.
    Cockey CD
    AWHONN Lifelines; 2004; 8(5):406-12. PubMed ID: 15560616
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.